HER2 (Phospho_Tyr877) Antibody
- Known as:
- HER2 (Phospho_Tyr877) Antibody
- Catalog number:
- E011075-2
- Product Quantity:
- 100ug
- Category:
- Antibodies
- Supplier:
- EnoGene
- Gene target:
- HER2 (Phospho_Tyr877) Antibody
Related genes to: HER2 (Phospho_Tyr877) Antibody
- Gene:
- ERBB2 NIH gene
- Name:
- erb-b2 receptor tyrosine kinase 2
- Previous symbol:
- NGL
- Synonyms:
- NEU, HER-2, CD340, HER2
- Chromosome:
- 17q12
- Locus Type:
- gene with protein product
- Date approved:
- 2001-06-22
- Date modifiied:
- 2019-04-23
Related products to: HER2 (Phospho_Tyr877) Antibody
Related articles to: HER2 (Phospho_Tyr877) Antibody
- Antibody-drug conjugates (ADCs) have transformed the treatment landscape of breast cancer and redefined the conceptual distinction between targeted therapy and conventional chemotherapy. Originally conceived as "magic bullets" that selectively deliver cytotoxic warheads to antigen-expressing tumor cells, clinical and mechanistic evidence indicates that ADC activity depends on a broader interplay of target-dependent and target-independent mechanisms, including extracellular payload release, bystander killing, off-tumor uptake, and immune modulation. Here, we examine ADCs in breast cancer as a distinct therapeutic paradigm. We discuss how antigen biology, linker chemistry, payload features, and drug-to-antibody ratio collectively determine efficacy, toxicity, and therapeutic index. We then compare currently approved and emerging HER2- and TROP2-directed ADCs, highlighting how differences in linker stability, payload pharmacology, and bystander capacity can affect clinical outcomes in ADCs sharing the same target. We further discuss the biological basis and translational challenges of de novo and acquired resistance related to targets, payloads, and tumor microenvironmental constraints, as well as the implications of these mechanisms for biomarker development, sequencing rationales, and combination strategies with immune checkpoint inhibitors and DNA repair-targeting therapies. Finally, we outline future directions of ADC development, including expansion of the target space, novel payload modalities, and next-generation antibody and conjugation engineering. - Source: PubMed
Publication date: 2026/10/01
Guo ChenxuEllisen Leif W - Immunotherapy has revolutionized the therapeutic landscape for many cancers, but its application in solid tumors has lagged. There is now evidence that immunotherapy can improve outcomes in triple-negative breast cancer, but hormone receptor-positive (HR+) breast cancer has traditionally been considered immunologically cold. However, emerging evidence challenges this binary paradigm, suggesting that a biologically relevant subset of HR+/human epidermal growth factor receptor 2-negative (HER2-) tumors exhibit meaningful immunogenic features and clinically relevant sensitivity to immune-based treatment. In this Review we summarize the current understanding of immunogenicity and clinical use of immune-based treatments across breast cancer subtypes. We argue for a broader view of a spectrum of breast cancer immunogenicity and highlight the importance of host factors, including parity and lactation history, in shaping antitumor immunity. Improved identification of immunologically active subsets and deeper mechanistic insight will be essential to expand the therapeutic benefit of immunotherapy to broader patient cohorts and to refine care of patients with breast cancer. - Source: PubMed
Publication date: 2026/10/01
Kay JasmineDixon-Douglas Julia RHarris Michael Avan Geelen Courtney TLoi Sherene - Ramucirumab (RAM) plus taxane is the standard second-line treatment for unresectable advanced gastric cancer (AGC). However, the clinical outcomes of this regimen after immune checkpoint inhibitor (ICI)-based first-line therapy remain unclear, particularly in patients who exhibit progressive disease (PD) as the best overall response to prior treatment. - Source: PubMed
Yamaguchi KazuhisaKikuchi YoshinoriWakabayashi MunehiroKayashima MichikoShiratori FumiakiSuzuki TakashiOshima YokoYajima SatoshiMatsuda Takahisa - Human epidermal growth factor receptor 2 (HER2)-low breast cancer shows consistently low pathological complete response (pCR) rates after neoadjuvant chemotherapy (NAC), yet no preoperative tool exists to identify non-responders for whom alternative strategies - including upfront surgery or early trastuzumab deruxtecan (T-DXd) - may be considered. We investigated whether a three-factor model using routinely available pretreatment data could identify this chemoresistant subgroup. - Source: PubMed
Fuse YoshinobuFushimi AtsushiNameki AyanoKawase KazumiNogi Hiroko - The optimal management of close resection margins after breast-conserving surgery (BCS) remains controversial, particularly in hormone receptor-negative (HR-) breast cancer, which has a relatively high risk of local recurrence (LR). This study evaluated the association between resection margin width and LR and identified high-risk factors among patients with close margins. - Source: PubMed
Chang Won IckJang Bum-SupChang Ji HyunKim KyuboShin Kyung Hwan